Abstract 14770: Reduction With Evolocumab in Complex Coronary Disease Requiring Revascularization: Insights From the FOURIER Trial

医学 传统PCI Evolocumab公司 血运重建 心脏病学 内科学 经皮冠状动脉介入治疗 支架 心肌梗塞 外科 载脂蛋白B 胆固醇 载脂蛋白A1
作者
Kazuma Oyama,Remo H M Furtado,Antônio Fagundes,Thomas A. Zelniker,Minao Tang,Julia Kuder,Sabina A. Murphy,Andrew Hamer,Huei Wang,Anthony Keech,Terje R. Pedersen,Robert P. Giugliano,Marc S. Sabatine,Brian Bergmark
出处
期刊:Circulation [Lippincott Williams & Wilkins]
卷期号:142 (Suppl_3) 被引量:3
标识
DOI:10.1161/circ.142.suppl_3.14770
摘要

Introduction: Although PCSK9 inhibitors induce plaque regression and reduce the risk of coronary revascularization overall, their ability to specifically reduce the risk of complex coronary atherosclerosis requiring revascularization has not been explored. Methods: FOURIER was a randomized trial of the PCSK9 inhibitor evolocumab vs. placebo in 27,564 patients with ASCVD on statin therapy (median achieved LDL-C 32 mg/dL vs. 89 mg/dL) followed for a median of 2.2 years. The study database was blindly reviewed to assess characteristics of coronary revascularization procedures. Complex revascularization was the composite of complex PCI (per GLOBAL LEADERS criteria, at least one of: multivessel PCI, 3 or more stents implanted, 3 or more lesions treated, bifurcation PCI with 2 or more stents, or total stent length >60 mm) or CABG. PCI complications included no-reflow, side branch loss, thrombus formation, major dissection, or perforation. The effects of evolocumab on types of revascularization and PCI complications were evaluated using Cox proportional hazards models. Results: 1724 patients underwent revascularization procedures during follow-up. Evolocumab reduced the risk of non-complex PCI by 22% (HR 0.78; 95%CI 0.70-0.88; P<0.001) and the risk of complex revascularization by 29% (HR 0.71; 95%CI 0.61-0.84; P<0.001), including complex PCI by 33% (HR 0.67; 95%CI 0.54-0.84; P<0.001) and CABG by 24% (HR 0.76; 95%CI 0.60-0.96; P=0.019; Figure). The incidence of reported PCI complications tended to be lower with evolocumab (HR 0.74; 95% CI 0.49-1.11). Conclusions: Adding evolocumab to statin therapy reduced the risk of developing complex coronary disease requiring revascularization, including complex PCI and CABG individually. Together with prior coronary imaging findings, these data suggest very aggressive LDL-C lowering to <1 mmol/L has beneficial effects on coronary atherosclerosis burden, anatomical complexity, and the need for intervention.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
充电宝应助上官天宇采纳,获得10
2秒前
华仔应助科研通管家采纳,获得10
2秒前
汉堡包应助科研通管家采纳,获得10
2秒前
充电宝应助科研通管家采纳,获得10
2秒前
所所应助科研通管家采纳,获得10
2秒前
拼豆豆应助科研通管家采纳,获得10
2秒前
SciGPT应助科研通管家采纳,获得10
2秒前
爆米花应助科研通管家采纳,获得10
2秒前
3秒前
ookyze完成签到,获得积分10
3秒前
3秒前
cocaco应助科研通管家采纳,获得30
3秒前
小马甲应助科研通管家采纳,获得30
3秒前
啵啵应助科研通管家采纳,获得10
3秒前
拼豆豆应助科研通管家采纳,获得10
3秒前
乐乐应助科研通管家采纳,获得10
3秒前
zhy发布了新的文献求助10
3秒前
huang应助科研通管家采纳,获得10
3秒前
白石人家应助科研通管家采纳,获得10
3秒前
斯文败类应助科研通管家采纳,获得10
3秒前
3秒前
4秒前
李健应助红红采纳,获得10
4秒前
称心书蝶完成签到 ,获得积分10
5秒前
5秒前
RB完成签到,获得积分10
6秒前
advance完成签到,获得积分0
6秒前
博慧完成签到 ,获得积分10
7秒前
ttx发布了新的文献求助10
7秒前
8秒前
8秒前
仁爱思天发布了新的文献求助10
9秒前
9秒前
v0id应助虚心白凡采纳,获得10
9秒前
悠南完成签到 ,获得积分10
10秒前
现代天空发布了新的文献求助10
10秒前
11秒前
123发布了新的文献求助10
11秒前
Lunanar完成签到,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 2500
Evidence Summary. Injection (subcutaneous):op- timal administration 1000
悉尼大学博士学位论文,题目:Modelling and testing of one-sided stitched laminated composites. 作者:Kristopher P. Plain 700
Matrix Methods in Data Mining and Pattern Recognition Second Edition 610
Curating Socialism: A Handbook of International Art Exhibitions 1947-1989 530
Soil mites of the family Rhagidiidae (Actinedida: Eupodoidea). Morphology, Systematics, Ecology 520
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7468819
求助须知:如何正确求助?哪些是违规求助? 9063864
关于积分的说明 19323636
捐赠科研通 7089180
什么是DOI,文献DOI怎么找? 3245173
关于科研通互助平台的介绍 2413867
邀请新用户注册赠送积分活动 2230216